TrialThe oncologist2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
Naoto T Ueno et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this papertrialcites it